Cruentaren, a New Antifungal Salicylate-Type Macrolide from Byssovorax cruenta (Myxobacteria) with Inhibitory Effect on Mitochondrial ATPase Activity

Fermentation and Biological Properties

Brigitte Kunze, Heinrich Steinmetz, Gerhard Höfle, Markus Huss, Helmut Wieczorek, Hans Reichenbach

Received: June 30, 2006 / Accepted: October 12, 2006
© Japan Antibiotics Research Association

Abstract The novel macrolide cruentaren A was produced at levels up to 3.2 mg/liter by cultures of the myxobacterium Byssovorax cruenta. The new compound strongly inhibited the growth of yeasts and filamentous fungi and showed high cytotoxicity against L929 mouse fibroblast cells. A minor co-metabolite of cruentaren A, named cruentaren B, and identified as a six-membered lactone isomer of cruentaren A, showed only marginal cytotoxicity and no antifungal activity. Cruentaren A inhibited F0F1 mitochondrial ATP-hydrolysis in submitochondrial particles of yeasts and beef heart.

Keywords myxobacteria, cruentaren, benzolactone class antifungal, cytotoxic, F0F1 ATPase

B. Kunze (Corresponding author), H. Steinmetz, G. Höfle, H. Reichenbach: Helmholtz Centre for Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig, Germany,
E-mail: brigitte.kunze@helmholtz-hzi.de
M. Huss, H. Wieczorek: Department of Biology/Chemistry, University of Osnabrück, D-49069 Osnabrück, Germany
Article No. 104 on antibiotics from gliding bacteria. Article No.103: Niggemann J, Bedorf N, Flörke U, Steinmetz H, Gerth K, Reichenbach H, Höfle G. Eur J Org Chem 2005: 5015-5018 (2005)